Pharmacyte Biotech, INC 10-Q quarterly reports

PharmaCyte Biotech reported a significant net loss for the nine months ended January 31, 2026, while addressing an ongoing FDA clinical hold and Nasdaq minimum bid price non-compliance.

PharmaCyte Biotech, Inc. reported a significant net loss for the second quarter and six months ended October 31, 2025, while facing a Nasdaq minimum bid price non-compliance notice and ongoing FDA clinical hold challenges.

PharmaCyte Biotech reported a significant net loss in Q1 2026, driven by fair value adjustments, as it continues to address an FDA clinical hold and re-evaluate its core programs.

PharmaCyte Biotech's Q3 2025 report highlights efforts to address the FDA clinical hold, investment in TNF Pharmaceuticals, and a decrease in operating expenses.

PharmaCyte Biotech's Q2 2025 report reveals a significant net income driven by investment gains, alongside ongoing efforts to address an FDA clinical hold on their pancreatic cancer therapy.

PharmaCyte Biotech reports a significant net income for the first quarter of 2025, primarily driven by gains from investments, despite ongoing operational challenges and a clinical hold on their lead program.

PharmaCyte Biotech's Q3 2024 results show a net loss, ongoing efforts to address an FDA clinical hold, and a strategic review impacting development programs.